A Phase II trial demonstrated that combining irreversible electroporation (IRE) with β-glucan significantly improved disease-free intervals and overall survival in patients with stage III pancreatic ductal adenocarcinoma. The study included 30 patients treated with IRE followed by β-glucan, showing a median disease-free interval of 18 months and a median overall survival of 32.5 months. Notably, immunophenotyping revealed enhanced anti-tumor responses, highlighting the potential of this combination therapy.
Journal Article by Martin RC, Li Y (…) Yan J et 7 al. in J Am Coll Surg
Copyright © 2025 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.